Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:DARE NASDAQ:ENGN NASDAQ:LIXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.75-3.8%$2.60$1.75▼$4.94$104.29M3.222.17 million shs2.31 million shsDAREDare Bioscience$2.02-0.5%$2.25$1.27▼$9.19$30.41M1.07291,844 shs92,812 shsENGNenGene$1.62-1.2%$4.41$1.40▼$12.25$109.86M-0.31.15 million shs456,532 shsLIXTLixte Biotechnology$6.19-14.6%$4.74$0.64▼$7.51$108.89M1.27211,115 shs871,824 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-1.62%-13.13%-35.69%-14.15%-23.21%DAREDare Bioscience+1.50%-6.88%-22.81%+40.97%-37.54%ENGNenGene+2.50%-4.65%+13.89%-77.09%-49.07%LIXTLixte Biotechnology+5.22%+3.57%+43.00%+133.12%+489.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.75-3.8%$2.60$1.75▼$4.94$104.29M3.222.17 million shs2.31 million shsDAREDare Bioscience$2.02-0.5%$2.25$1.27▼$9.19$30.41M1.07291,844 shs92,812 shsENGNenGene$1.62-1.2%$4.41$1.40▼$12.25$109.86M-0.31.15 million shs456,532 shsLIXTLixte Biotechnology$6.19-14.6%$4.74$0.64▼$7.51$108.89M1.27211,115 shs871,824 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-1.62%-13.13%-35.69%-14.15%-23.21%DAREDare Bioscience+1.50%-6.88%-22.81%+40.97%-37.54%ENGNenGene+2.50%-4.65%+13.89%-77.09%-49.07%LIXTLixte Biotechnology+5.22%+3.57%+43.00%+133.12%+489.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.73Moderate Buy$10.00471.43% UpsideDAREDare Bioscience 2.33Hold$10.00395.05% UpsideENGNenGene 2.21Hold$12.68682.83% UpsideLIXTLixte Biotechnology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest DARE, ENGN, BDTX, and LIXT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026BDTXBlack Diamond Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026BDTXBlack Diamond Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/15/2026ENGNenGene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026ENGNenGene UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$9.00 ➝ $2.005/12/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/8/2026ENGNenGene Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$4.005/8/2026ENGNenGene Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$7.00 ➝ $4.005/8/2026ENGNenGene CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeMarket Outperform ➝ Market Perform(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M1.43$0.51 per share3.45$1.97 per share0.89DAREDare Bioscience$1.03M29.38N/AN/A$0.20 per share10.10ENGNenGeneN/AN/AN/AN/A$2.60 per shareN/ALIXTLixte BiotechnologyN/AN/AN/AN/A$1.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%8/6/2026 (Estimated)DAREDare Bioscience-$13.40M-$0.95N/AN/AN/AN/AN/A-46.22%8/13/2026 (Estimated)ENGNenGene-$117.30M-$2.25N/AN/AN/AN/A-55.83%-45.74%N/ALIXTLixte Biotechnology-$6.01M-$1.13N/AN/AN/AN/A-134.91%-95.61%N/ALatest DARE, ENGN, BDTX, and LIXT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026DAREDare Bioscience-$0.33-$0.20+$0.13-$0.21$0.03 million$0.15 million5/14/2026Q1 2026LIXTLixte BiotechnologyN/A-$0.18N/A-$0.18N/AN/A5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/A3/26/2026Q4 2025DAREDare Bioscience-$0.44-$0.02+$0.42-$0.02$0.75 million$1.02 million3/16/2026Q4 2025BDTXBlack Diamond Therapeutics-$0.18-$0.14+$0.04-$0.27$9.38 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ADAREDare BioscienceN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.468.46DAREDare BioscienceN/A1.031.03ENGNenGene0.0911.7511.75LIXTLixte BiotechnologyN/A2.782.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%DAREDare Bioscience6.70%ENGNenGene64.16%LIXTLixte Biotechnology5.10%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics9.29%DAREDare Bioscience4.10%ENGNenGene10.50%LIXTLixte Biotechnology9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableDAREDare Bioscience3014.98 million14.37 millionNot OptionableENGNenGene3166.99 million59.95 millionN/ALIXTLixte Biotechnology415.02 million13.59 millionNot OptionableDARE, ENGN, BDTX, and LIXT HeadlinesRecent News About These CompaniesThe New Bottleneck Isn’t Computing Power — It’s Just Power2 hours ago | markets.businessinsider.comFrom Cancer Drugs to Kilowatts: A NASDAQ Company's Bet on the AI Power Crunch2 hours ago | newswire.caLixte Biotechnology Shares Down on Plans for Nomad Transportable Power Deal, Name Change2 hours ago | marketwatch.comLIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)June 12 at 8:30 AM | globenewswire.comLixte Biotechnology Announces At-the-Market Equity FinancingJune 4, 2026 | tipranks.comLIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic GrowthJune 3, 2026 | globenewswire.comLIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of DirectorsJune 1, 2026 | globenewswire.comLixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest UpdateJune 1, 2026 | americanbankingnews.comLIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress UpdateMay 14, 2026 | globenewswire.comLIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer TreatmentApril 28, 2026 | finance.yahoo.comLIXTE Biotechnology Holdings (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer TreatmentApril 27, 2026 | financial-news.co.ukLIXTE Biotechnology Holdings (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment LandscapeApril 21, 2026 | financial-news.co.ukLixte Biotechnology Updates Executive Equity Compensation With RSUsApril 17, 2026 | tipranks.comLIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO ConferenceApril 13, 2026 | usatoday.comFavorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care ConferenceApril 13, 2026 | globenewswire.comLixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic PartnershipsApril 10, 2026 | financial-news.co.ukLixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic PartnershipsApril 10, 2026 | finance.yahoo.comLixte Biotechnology Holdings, Inc.April 7, 2026 | cnn.comLIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational YearApril 4, 2026 | usatoday.comLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative YearApril 1, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDARE, ENGN, BDTX, and LIXT Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$1.75 -0.07 (-3.85%) Closing price 04:00 PM EasternExtended Trading$1.80 +0.04 (+2.57%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Dare Bioscience NASDAQ:DARE$2.02 -0.01 (-0.49%) Closing price 04:00 PM EasternExtended Trading$2.03 +0.01 (+0.69%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.enGene NASDAQ:ENGN$1.62 -0.02 (-1.22%) Closing price 04:00 PM EasternExtended Trading$1.63 +0.01 (+0.62%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Lixte Biotechnology NASDAQ:LIXT$6.19 -1.06 (-14.62%) Closing price 04:00 PM EasternExtended Trading$6.42 +0.23 (+3.80%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
